Home Multimedia Exclusive Videos Exclusive VideosMultimedia ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients Sunday, January 1, 2017 Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit FLT3 in relapsed/refractory AML patients. Advertisement Recent Articles House Speaker Pelosi to Release Medicare Drug Pricing Bill Thursday, September 19, 2019 House Speaker Nancy Pelosi (D-CA) is expected to release a bill that would allow the U.S. Secretary of Health and Human Services to negotiate... Could CRISPR Help Parents of Sick Children Conceive Savior Siblings? Thursday, September 19, 2019 In 2018, He Jiankui, PhD, stirred controversy when he modified the DNA of twin embryos using CRISPR to mitigate HIV risk. Now, investigators are... Despite Right-to-Try Laws, Most Drug Makers Still Require FDA Reviews Thursday, September 19, 2019 The “Right-to-Try” law, which President Donald Trump signed in May 2018, allows more direct access to experimental drugs for terminally ill patients who have... Purdue Pharma Files for Bankruptcy Thursday, September 19, 2019 OxyContin manufacturer Purdue Pharma has filed for bankruptcy as part of what will be the first settlement related to the opioid crisis. Under this... 2020 Democratic Presidential Candidates Disagree on Health Care Thursday, September 19, 2019 In the recent Democratic primary debates, the top 2020 Democratic U.S. presidential candidates each proposed vastly different approaches to universal health care. Candidates in favor... Current Issue September 2019, Volume 5, Issue 11 Sunday, September 1, 2019 This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.